XNASBBLG
Market cap2mUSD
Dec 24, Last price
0.95USD
1D
-3.88%
1Q
-59.06%
IPO
-99.99%
Name
Bone Biologics Corp
Chart & Performance
Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 9,428 | 3,665 | 1,101 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (9,428) | (3,665) | (1,101) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (2,181) | 2 | ||||||||
Tax Rate | ||||||||||
NOPAT | (9,428) | (1,485) | (1,103) | |||||||
Net income | (8,949) -1,385.86% | 696 -143.21% | (1,611) -11.73% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 5,044 | 4,430 | 6,859 | |||||||
BB yield | -424.10% | -184.93% | -42.90% | |||||||
Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (3,027) | (7,538) | (6,675) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (9,556) | (3,567) | (1,229) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 5,044 | 4,430 | 7,904 | |||||||
FCF | (9,428) | (1,485) | (3,073) | |||||||
Balance | ||||||||||
Cash | 3,027 | 7,538 | 6,675 | |||||||
Long term investments | ||||||||||
Excess cash | 3,027 | 7,538 | 6,675 | |||||||
Stockholders' equity | (80,908) | (71,945) | (70,465) | |||||||
Invested Capital | 83,815 | 77,109 | 77,041 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 263 | 48 | 19 | |||||||
Price | 4.52 -91.02% | 50.33 -94.04% | 844.80 | |||||||
Market cap | 1,189 -50.35% | 2,395 -85.02% | 15,987 | |||||||
EV | (1,837) | (5,143) | 9,312 | |||||||
EBITDA | (9,428) | (3,665) | (1,101) | |||||||
EV/EBITDA | 0.19 | 1.40 | ||||||||
Interest | 2,181 | 805 | ||||||||
Interest/NOPBT |